Navigation Links
Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time
Date:7/28/2011

DUBLIN, July 28, 2011 /PRNewswire/ --

 

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces results for the three months to June 30, 2011.

Financial Highlights Q2 2011(1) Product sales $993 million +30% Total revenues $1,063 million +25% Non GAAP operating income $342 million +26% US GAAP operating income $283 million +26% Non GAAP diluted earnings per ADS $1.33 +29% US GAAP diluted earnings per ADS $1.08 +26% Non GAAP cash generation $440 million +7% Non GAAP free cash flow $235 million -1% US GAAP net cash provided by operating activities $284 million 0%

(1) Percentages compare to equivalent period in 2010.

The Non GAAP financial measures included within this release are explained on page 25, and are reconciled to the most directly comparable financial measures prepared in accordance with US GAAP on pages 20 - 24.

Angus Russell, Chief Executive Officer, commented:

"It's been another strong quarter with Shire continuing to perform very well. Total revenues were up 25% and for the first time exceeded $1billion for the quarter and we have reported a 29% increase in Non GAAP diluted earnings per ADS.

Product sales increased by 30%. Our rare disease treatments are performing well around the world; the FDA Advisory Committee recommended approval and self administration of FIRAZYR for acute attacks of Hereditary Angioedema and we're now preparing for a US launch, in anticipation of what we hope will be an FDA approval in August. We're very pleased that the European Medicines Agency has approved the purification of REPLAGAL for Fabry disease at our new facility in Massachusetts, giving us increased manufacturing flexibility.

Sales of our ADHD products increased significantly in the US market, driven by increasing market share and further strong market growth. In
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. Neogen Reports 27% Increase in Quarterly Net Income
2. Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be
3. Microbix Has Best-Ever Quarterly Sales
4. Amylin Pharmaceuticals Announces Third Quarter Product Revenues; Quarterly Update Conference Call Canceled
5. China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010
6. Shires Replenished Portfolio Drives Excellent Quarterly Performance
7. Quest Diagnostics Declares Quarterly Cash Dividend
8. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
9. Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
10. Abbott Declares 343rd Consecutive Quarterly Dividend
11. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... /PRNewswire-iReach/ -- DeepResearchReports.com adds "2014 Deep Research Report ... "2014 Deep Research Report on Global and China ... Photo - http://photos.prnewswire.com/prnh/20140918/147058 ... and China Acetic Acid Industry" is a professional ... and Global Acetic Acid Market. The ...
(Date:9/18/2014)...  Health Enhancement Products, Inc. (OTCQB: HEPI), a ... and metabolic processes, is pleased to announce the addition of ... Nola E. Masterson , a California ... September 17, 2014. "We,re very pleased and ... states Andrew Dahl , President and CEO. "She joins ...
(Date:9/18/2014)... Texas (PRWEB) September 18, 2014 ... Chancellor John Sharp, Texas A&M Health Science Center ... U.S. Department of Health and Human Services (HHS), ... dedicated a national pandemic influenza vaccine manufacturing facility ... as an anchor for the Texas A&M Biocorridor ...
(Date:9/18/2014)... -- Research and Markets has announced the ... Industry Report, 2014-2017" report to their offering. ... can differentiate into specialized cells and can divide (through ... can be applied to treatment of cardiovascular diseases, leukemia ... damage or lesion of liver, kidney and other parenchymal ...
Breaking Biology Technology:Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3
... Mass., March 11 Pressure,BioSciences, Inc. (Nasdaq: ... has joined PBI,s senior executive management team as ... nearly twenty years of experience in,sales and sales ... companies.,Mr. Potter will oversee PBI,s seven US-based, regional ...
... Lack of Flulike Side-Effects Drives Physician Prescribing of Copaxone over ... ... Resources, WALTHAM, Mass., ... advisory firms focusing on pharmaceutical and,healthcare issues, finds that Teva Pharmaceutical,s ...
... Inc.,(Nasdaq: RDEA ) today announced that Barry ... will present at Cowen and Company,s 28th Annual,Health ... Time: 4:40 p.m. Eastern Time, Location: ... Webcast:, http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=RDEA&item_id=1 ,779991, About ...
Cached Biology Technology:Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales 2Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales 3Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales 4Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis 2Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis 3Ardea to Present at Cowen and Company's 28th Annual Health Care Conference 2
(Date:9/18/2014)... Bulletin study uses tree rings to document arroyo ... in northern New Mexico, USA. By determining burial dates ... were able to precisely date arroyo sedimentary beds 30 ... with aerial imagery, LiDAR, longitudinal profiles, and repeat surveys ... are deep, oversized channels that have vertical or steeply ...
(Date:9/18/2014)... A team of researchers from McGill University and ... form of polyethylene ,microbeads, Canadian Journal of ... likely originate from cosmetics, household cleansers, or industrial ... abrasives. Owing to their small size and buoyancy, ... Microplastics are a global contaminant in the ...
(Date:9/18/2014)... DNA, tiny strands of nucleic acid that contain instructions ... genetic data, our DNA is copied into RNA molecules, ... tasks in our cells. , Several years ago, ... all other known RNAs, this molecule is circular, and ... little has been known about how they are produced. ...
Breaking Biology News(10 mins):Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7Microplastic pollution discovered in St. Lawrence River sediments 2Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2
... largest mass extinction in the history of animal life occurred ... percent of marine species and 70 percent of life on ... the Earth. Multiple theories have aimed to explain the cause ... asteroid impact, massive volcanic eruptions, or a cataclysmic cascade of ...
... from Massachusetts Eye and Ear, Harvard Medical School, and ... system-on-chip (SoC) that could make possible a fully implanted ... 11at the IEEE International Solid State Circuits Conference in ... that electronically stimulates the auditory nerve to restore hearing ...
... patients who required care at Duke University Hospital during this ... vaccinated had severe cases and needed the most intensive treatment. ... treated for flu at the academic medical center from November ... only two of the 22 patients who required intensive care ...
Cached Biology News:Giant mass extinction may have been quicker than previously thought 2Giant mass extinction may have been quicker than previously thought 3Design prototype chip makes possible a fully implantable cochlear implant 2Young, unvaccinated adults account for severest flu cases 2
No description available in Ensembl. Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Protein YIPF6 (YIP1 family member 6). [Source:Uniprot/SWISSPROT;Acc:Q96EC8] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
... U.S. sourced, ideal for those ... Low hemoglobin; Endotoxin: < 1.0 ... US origin; U.S. sourced, ideal ... uncompromising quality. Low hemoglobin Endotoxin: ...
Chicken polyclonal to ytzF ( Abpromise for all tested applications). Antigen: Full length protein...
Biology Products: